HOME >> BIOLOGY >> NEWS
Brandeis and Brigham and Women's Hospital license technology for Gaucher's to Amicus Therapeutics

Waltham, MABrandeis University and Brigham and Women's Hospital today agreed to grant a license option to Amicus Therapeutics for a jointly-developed novel pharmaceutical technology that could be instrumental in finding new treatments for Gaucher Disease. Biochemists Raquel Lieberman, Gregory Petsko and Dagmar Ringe, each affiliated with both Brandeis and Brigham and Women's, invented a patentable technology related to the structure of acid beta-glucosidase, also known as GCase, and methods for identifying therapeutic agents. In collaboration with scientists at Amicus Therapeutics, the inventors discovered that GCase, the protein that is mutated in Gaucher Disease, undergoes a structural change near its active site upon binding to a small molecule that is in clinical trials for the treatment of the disease.

One emerging type of treatment for genetic diseases such as Gaucher Disease involves the use of small molecules known as pharmacological chaperones, which are proposed to help mutated, less stable proteins perform their normal function in the cells of patients with the disease. The identification of appropriate pharmacological chaperones and understanding how they work in the body are aided by knowing the structure of the target protein under different conditions and when bound to the small molecule.

Cranbury, New Jersey-based Amicus Therapeutics, which specializes in the discovery and development of pharmacological chaperones, will use this structure of GCase to look for additional small molecules that can keep the protein properly folded and stabilized.

"This work helps explain the way pharmacological chaperones work to stabilize proteins that are rendered less stable by genetic mutations in diseases such as Gaucher, Anderson-Fabry, and other genetic disorders," explained Petsko, the Gyula and Katica Tauber Professor of Biochemistry and Chemistry, Brandeis University and Adjunct Professor, Department of Neurology and Center
'"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
22-Feb-2007


Page: 1 2

Related biology news :

1. New Brandeis research sheds light on memory by erasing it
2. National Academy of Sciences elects 2 Brandeis University scientists to membership
3. Biogen Idec acquires Brandeis spin-out
4. HHMI awards Brandeis professor $1 million to draw minorities into science
5. Carl and Ruth Shapiro family donates $25 million for new science center at Brandeis University
6. American Physical Society honors outstanding achievements of two Brandeis scientists
7. Brandeis biologist wins top award in neuroscience
8. Brandeis wins $1 million grant to train scientists in solving 21-century biomedical problems
9. AAAS and Brandeis University announce 2005 Fellows
10. Brandeis leads collaborative team in researching chemical processes in brain
11. MIT, Brigham: Nanoparticles armed to combat cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology:
Cached News: